The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step ...

MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...

If we don’t invest in technologies like mRNA vaccines for pandemic influenza now, once a virus starts going human-to-human, ...

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential pandemic influenza viruses, including the H5N1 bird flu.

In 2023, Moderna started a phase 1/2 study of an experimental pandemic influenza vaccines collectively known as mRNA-1018, which are designed to provide protection against H5 and H7 avian ...

Funding for a potential bird flu vaccine was recently pulled. Moderna expects to end 2025 with $6bn in cash. And analysts see revenue growth resuming in 2026, rising 16% to $2.4bn. Then up another 25% ...

The healthcare sector, represented by the Health Care Select Sector SPDR Fund (NYSEARCA:XLV), underperformed the broader ...

Trump and Musk reignite feud over tax bill, stocks end first half at records, Moderna flu vaccine achieves promising results, ...

The most powerful public health official in the US is reviled by some medics - but even some of his critics accept that he is ...